SCHEMBL4997771

SCHEMBL4997771

N#Cc1nnc(NCc2ccccc2)c2ccc(C(=O)O)cc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 5/20 0.51
CSNK2A2 P19784 2/20 0.51
CSNK2B P67870 1/20 0.51
ALDH1A1 P00352 4/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
HTT P42858 2/20 0.47
HPGD P15428 2/20 0.47
TP53 P04637 1/20 0.47
VNN1 O95497 2/20 0.43
KDM4E B2RXH2 2/20 0.42
HSD17B10 Q99714 2/20 0.42
CRHBP P24387 1/20 0.42
CRHR2 Q13324 1/20 0.42
USP2 O75604 1/20 0.42
LMNA P02545 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
ALOX15 P16050 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4990856 0.81 CSNK2A1 (0.54) CSNK2A1CSNK2A2CSNK2BALDH1A1MEN1
SCHEMBL4990576 0.81 CSNK2A1 (0.54) CSNK2A1CSNK2A2CSNK2BALDH1A1MEN1
SCHEMBL4991481 0.80 SLC22A12 (0.40) CSNK2A1CSNK2A2CSNK2BALDH1A1MEN1
SCHEMBL2462200 0.80 KDR (0.53) ALDH1A1MEN1KMT2AHTTHPGD
SCHEMBL4986819 0.79 CSNK2A1 (0.51) CSNK2A1CSNK2A2CSNK2BALDH1A1MEN1
SCHEMBL4991734 0.79 CSNK2A1 (0.51) CSNK2A1CSNK2A2CSNK2BALDH1A1MEN1
SCHEMBL4996128 0.75 HCAR3 (0.39) CSNK2A1CSNK2A2CSNK2BALDH1A1HPGD
SCHEMBL4987535 0.74 CSNK2A1 (0.57) CSNK2A1CSNK2A2CSNK2BALDH1A1MEN1
SCHEMBL2459765 0.70 PPARG (0.49) ALDH1A1MEN1KMT2AHTTHPGD
SCHEMBL4991745 0.69 SLC22A12 (0.40) CSNK2A1CSNK2A2CSNK2BALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349836-B2 Phthalazine derivatives as inhibitors of protein kinase ARALDI GIAN-LUCA (US) 2013-01-08 US claimed
US-20080146547-A1 PHTHALAZINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-06-19 US claimed
US-8349836-B2 Phthalazine derivatives as inhibitors of protein kinase ARALDI GIAN-LUCA (US) 2013-01-08 US disclosed
EP-2131656-A2 PHTHALAZINE DERIVATIVES Forest Laboratories Holdings Limited (BM) 2009-12-16 EP disclosed
US-20080146547-A1 PHTHALAZINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-06-19 US disclosed
WO-2008061108-A2 PHTHALAZINE DERIVATIVES FOREST LABORATORIES HOLDINGS LIMITED (BM) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146547-A1 PHTHALAZINE DERIVATIVES CDK5, HIPK2, PACSIN2 CSNK2A1 60/4885CSNK2A2 59/4885CSNK2B 114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.